NOS2 and breast carcinoma: Besides, the overall survival time of breast cancer patients with at least one gene mutation in PRKDC, NOS2, ARG1, and IDO1 (1191 patients) was significantly shorter compared with patients without the mutations (4575 patients) (Figure 2E).